Allowances Further Strengthen Company's Leading microRNA Intellectual
Company's microRNA Patent Portfolio now Includes 2 Issued Patents, 2
Allowed Patents, and More Than 60 Pending Patent Applications
REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, March 3 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of the company's patent applications on human (10/604,726) and viral (10/604,942) microRNAs. The first allowed patent application (10/604,726) is related to two clustered human hairpins and their related microRNAs. The second allowed patent application (10/604,942) is related to microRNA US5-1, a viral microRNA found in Human cytomegalovirus (HCMV), a member of the herpes virus family.
"Our leading intellectual property portfolio in microRNAs, which now includes two issued and two allowed patents, is a key component of our business strategy," said Amir Avniel, President and CEO of Rosetta Genomics. "Combining our proprietary microRNAs with microRNAs discovered in collaboration with Johns Hopkins University exclusively licensed to Rosetta Genomics, we believe we have exclusive access to the majority of known human and viral microRNA genes. In addition, we have in-licensed microRNAs from leading research institutes in this field. We believe this strong intellectual property position, will enable us to rapidly expand our pipeline and advance new microRNA-based diagnostics for a wide range of indications."
Rosetta Genomics has filed dozens of patent applications protecting
composition-of-matter of human and viral microRNAs. These patent
applications are related to hundreds of human and viral microRNAs
sequences. The patent applications are directed to a wide range of
variations, including mutations on the mature microRNA, the microRNAs'
precursor and its predic
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved